Loading…
Coya Therapeutics, Inc. is projected to rise to $5.27 by 2027, a +26% move from its current price of $4.19. COYA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/3/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $4.06 | $4.19 | $4.33 | +0.07% |
| Aug 6 | $4.01 | $4.20 | $4.40 | +0.15% |
| Aug 7 | $3.97 | $4.20 | $4.45 | +0.22% |
| Aug 8 | $3.94 | $4.20 | $4.49 | +0.29% |
| Aug 9 | $3.91 | $4.21 | $4.53 | +0.37% |
| Aug 10 | $3.88 | $4.21 | $4.56 | +0.44% |
| Aug 11 | $3.86 | $4.21 | $4.59 | +0.51% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.86 | $4.21 | $4.59 | +0.51% |
| Week 2 | $3.74 | $4.23 | $4.79 | +1.03% |
| Week 3 | $3.66 | $4.25 | $4.95 | +1.55% |
| Week 4 | $3.59 | $4.28 | $5.09 | +2.07% |
| Week 5 | $3.54 | $4.30 | $5.22 | +2.60% |
| Week 6 | $3.49 | $4.32 | $5.35 | +3.12% |
| Week 7 | $3.45 | $4.34 | $5.47 | +3.65% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.
The company develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages in Phase 2 trial for use in the treatment of amyotrophic lateral sclerosis, as well as frontotemporal dementia, Alzheimer's disease (AD), and Parkinson's disease. In addition, its pre-clinical product candidates include COYA 301, a low-dose interleukin 2 product candidate to treat AD; COYA 303, an investigational biologic combination of COYA 301 and a glucagon-like-peptide-1 receptor agonist for the treatment of inflammatory diseases; COYA 201, an antigen directed Treg-derived exosome product candidate to treat neurodegenerative, autoimmune, and metabolic diseases; COYA 206, an antigen directed Treg-derived exosome product candidate; and COYA 101. It has a collaboration with Dr.
Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. Coya Therapeutics, Inc. was founded in 2020 and is headquartered in Houston, Texas.
COYA is a Healthcare stock trading under the symbol COYA. The current price is $4.00 with a market capitalization of $93.83M and a rank of 4036.
The year-by-year forecast outlines a longer-term upside path, with the average price rising beyond the current level in several future years. The forward-looking view points to notable growth by 2030 and beyond, culminating in a projected higher average price by 2050.
A major floor 40.1% below — a decisive break under it would weaken the trend.
The nearest floor, 7.6% below — buyers have tended to step in here.
The nearest ceiling, 44.9% above — a clean break opens room to run.
A major ceiling 64.9% above — clearing it would confirm fresh momentum.
Key COYA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of COYA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.08 | Buy | $4.13 | Buy |
| MA 10 | $4.24 | Sell | $4.27 | Sell |
| MA 20 | $4.67 | Sell | $4.53 | Sell |
| MA 50 | $4.86 | Sell | $4.72 | Sell |
| MA 100 | $4.62 | Sell | $4.78 | Sell |
| MA 200 | $5.05 | Sell | $5.02 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 38.67 | Neutral |
| Stoch RSI (14) | 70.18 | Neutral |
| CCI (20) | -70.85 | Neutral |
| Williams %R (14) | -68.00 | Info |
| MACD (12,26,9) | -0.07 | Sell |
| ROC (12) | -13.43 | Sell |
| Bollinger %B (20,2) | 0.28 | Neutral |
| Stochastic %K (14) | 32.00 | Neutral |
| TRIX (15) | -0.59 | Sell |
| Awesome (5,34) | -0.86 | Sell |
| Ultimate (7,14,28) | 36.43 | Neutral |
| Momentum (10) | -0.35 | Sell |
| Aroon Osc (25) | -84.00 | Sell |
| Hull MA (9) | 3.95 | Buy |
| ADX (14) | 24.34 | Sell |
| ATR (14) | 0.15 | Info |
Technical sentiment is bearish at present. The RSI14 is 30, and the stock trades below the SMA50 of $4.94 and the SMA200 of $5.11, suggesting continuing near-term pressure. In the near term, support is identified at $4.26 and resistance at $6.07.
The 30-day range spans $3.24 to $4.94, highlighting a relatively tight trading window around the current price. Traders may watch for a shift in momentum if price test remains near support or breaks through resistance levels in the coming weeks.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.78 | $4.19 | $5.45 | 0% | Neutral | |
| $4.12 | $5.27 | $7.16 | +26% | Bullish | |
| $4.15 | $5.49 | $7.79 | +31% | Bullish | |
| $4.35 | $5.92 | $8.70 | +41% | Bullish | |
| $4.25 | $5.93 | $8.96 | +42% | Bullish | |
| $4.19 | $5.99 | $9.28 | +43% | Bullish | |
| $4.84 | $7.07 | $11.20 | +69% | Bullish | |
| $5.67 | $8.46 | $13.66 | +102% | Bullish | |
| $6.31 | $9.59 | $15.78 | +129% | Bullish | |
| $6.46 | $10.01 | $16.76 | +139% | Bullish | |
| $8.66 | $14.64 | $26.28 | +249% | Bullish | |
| $13.18 | $25.94 | $51.56 | +519% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $3.78 | $4.19 | $5.06 | +0.00% |
| September 2026 | $3.66 | $4.35 | $5.34 | +3.87% |
| October 2026 | $3.73 | $4.48 | $5.57 | +2.92% |
| November 2026 | $3.61 | $4.36 | $5.47 | -2.68% |
| December 2026 | $3.54 | $4.30 | $5.45 | -1.28% |
Click any year to see its month-by-month COYA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, COYA could reach as high as $5.45, with a base case around $4.19 and support toward $3.78 — roughly 0% from $4.19. A consolidation phase looks the most probable path here.
Expect COYA to range from $4.12 to $7.16 through 2027. The $5.27 average target implies a +26% move from current prices. That is up +26% on the projected 2026 average. Momentum favours further upside here.
The COYA price prediction for 2028 points to an average of $5.49 (low $4.15, high $7.79) — a potential gain of +31% on today's $4.19. Buyers look set to stay in control over this stretch.
In 2029, COYA is projected to trade between $4.35 and $8.70, averaging $5.92 — a potential gain of +41% from today's $4.19. That is up +8% on the projected 2028 average. Momentum favours further upside here.
Coya Therapeutics, Inc.'s 2030 outlook centres on $5.93, within a $4.25 to $8.96 range. That is up 0% on the projected 2029 average. That marks a +42% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, COYA could reach as high as $9.28, with a base case around $5.99 and support toward $4.19 — roughly +43% from $4.19. Momentum favours further upside here.
Expect COYA to range from $4.84 to $11.20 through 2032. The $7.07 average target implies a +69% move from current prices. That is up +18% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The COYA price prediction for 2033 points to an average of $8.46 (low $5.67, high $13.66) — a potential gain of +102% on today's $4.19. Momentum favours further upside here.
In 2034, COYA is projected to trade between $6.31 and $15.78, averaging $9.59 — a potential gain of +129% from today's $4.19. That is up +13% on the projected 2033 average. Buyers look set to stay in control over this stretch.
Coya Therapeutics, Inc.'s 2035 outlook centres on $10.01, within a $6.46 to $16.76 range. That is up +4% on the projected 2034 average. That marks a +139% change versus current levels. Momentum favours further upside here.
By 2040, COYA could reach as high as $26.28, with a base case around $14.64 and support toward $8.66 — roughly +249% from $4.19. Buyers look set to stay in control over this stretch.
Expect COYA to range from $13.18 to $51.56 through 2050. The $25.94 average target implies a +519% move from current prices. That is up +77% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in COYA today (≈ 238.663484 COYA) could be worth
$6,192.09
+$5,192.09 (+519%) by 2050 · US Dollar
Based on the average projected COYA price of $25.94 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in COYAwould be worth at today's price.
$1,000 invested in COYA on Jul 31, 2025 (≈ 168.067232 COYA) would be worth
$704.2
-$295.8 (-29.6%) today · 0.70× · US Dollar
Based on a COYA entry price of $5.95 vs. today's $4.19.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.25 | $985.88 | -1.4% |
| 1 month ago | $5.66 | $740.28 | -26.0% |
| 3 months ago | $4.17 | $1,004.8 | +0.5% |
| 6 months ago | $4.74 | $883.97 | -11.6% |
| 1 year ago | $5.95 | $704.2 | -29.6% |
| All time (3.6y) ago | $4.57 | $916.85 | -8.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our COYA forecast.
Our base-case forecast reaches $8.40 around 2033.
Implied market cap at $8.40: $197.04M
The multi-year forecast shows a bullish trajectory after a neutral start. The 2026 forecast lists a min of $3.78, an avg of $4.00, and a max of $5.21 with an ROI of 0 and sentiment Neutral.
From 2027 onward, the path strengthens: 2027 min $3.95, avg $5.03, max $6.81 with ROI 25.7 and sentiment Bullish; 2028 min $3.92, avg $5.17, max $7.32 with ROI 29.3 and sentiment Bullish; 2029 min $4.13, avg $5.59, max $8.18 with ROI 39.8 and sentiment Bullish; 2030 min $4.03, avg $5.59, max $8.41 with ROI 39.8 and sentiment Bullish; 2031 min $3.93, avg $5.58, max $8.60 with ROI 39.6 and sentiment Bullish.
Beyond 2031, the forecast continues higher: 2032 min $4.56, avg $6.63, max $10.43 with ROI 65.6 and sentiment Bullish; 2033 min $5.29, avg $7.83, max $12.56 with ROI 95.7 and sentiment Bullish; 2034 min $5.82, avg $8.79, max $14.36 with ROI 119.7 and sentiment Bullish; 2035 min $6.06, avg $9.31, max $15.46 with ROI 132.7 and sentiment Bullish.
The long-range outlook shows substantial upside later in the horizon: 2040 min $7.95, avg $13.27, max $23.63 with ROI 231.9 and sentiment Bullish; 2050 min $12.21, avg $23.62, max $46.45 with ROI 490.4 and sentiment Bullish. These figures illustrate a potential acceleration in value over the coming decades, though they are estimates and not guarantees.
Tap a question to reveal the answer.
The forecast shows an avg price of $5.59, with a min of $4.03 and a max of $8.41; ROI is 39.8 and the sentiment is Bullish.
Forecasts show a bullish trajectory in multiple years beyond 2026, with 2027 avg $5.03, 2028 avg $5.17, 2029 avg $5.59, 2030 avg $5.59, and 2031 avg $5.58; longer horizons point to higher averages and ROI (e.g., 2040 ROI 231.9 and 2050 ROI 490.4). These are estimates and not guarantees.
Yes. The max forecast for 2032 is $10.43; 2033 max is $12.56; 2034 max is $14.36; 2035 max is $15.46.
Current price is $4.00 and market cap is $93.83M.
The sentiment is BEARISH with RSI14 at 30. The SMA50 is $4.94 and the SMA200 is $5.11. Support is at $4.26 and resistance at $6.07. The 30-day range is $3.24 to $4.94.
Coya Therapeutics, Inc. Community Discussion
0Share your Coya Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.